Med-Cannabis Pharma, Inc. to Begin Recreational Retail Sales

BEND, OR / ACCESSWIRE / September 28, 2015 / Med-Cannabis Pharma, Inc. (PINKSHEETS: MCPI) a publicly-traded company focused on becoming the market leader in marijuana retail distribution, cultivation, and infused products in the emerging legal cannabis industry to begin early adult recreational retail sales in Oregon.

Beginning on October 1, 2015, medical dispensaries in Oregon may sell one quarter of an ounce of recreational marijuana to any adult over the age of 21. Although the state of Oregon has approved early adult recreational retail sales, city municipalities and counties have the option to decline and restrict adult recreational retail sales in their respective jurisdictions and many have chosen to do so.

“I am pleased to announce that all three of our dispensaries branded The Medication Station, will be participating in early adult recreational retail sales. The counties and cities where our stores are located have all been approved for early sales,” states Graciela Moreno, CEO of Med-Cannabis Pharma, Inc. “All our markets have expanded exponentially to include the adult recreational retail market, this is a huge opportunity and a major catalyst for our business.”

Graciela Moreno, will be a featured speaker on the upcoming online Cannabis Investor Webcast (www.cannawebcast.com) on October 8th, 2015 at 12:00 p.m. PDT or 3:00 p.m. EDT, where she will give a business overview and discuss the rollout of adult recreational retail sales.

The legal marijuana industry is among the fastest growing industries in Oregon. ArcView Market Research estimated sales of legal cannabis in Oregon totaled $54M in 2014. With the addition of adult recreational retail sales, we can assume ArcView Market Research estimates for Oregon will increase significantly year-over-year for 2015.

“With Oregon’s recreational marijuana market opening in less than one week, Med-Cannabis Pharma, Inc. is poised to see significant top-line growth on a quarter-over-quarter basis. Technical420 has initiated coverage on MCPI and we will be monitoring how the company executes on this rapidly growing market,” states Michael Berger, Founder of Technical420 Research Firm. “Currently, MCPI has three Oregon dispensaries which are operational and branded under the name The Medication Station. Recent share price weakness coupled with improving financials has put MCPI on our radar.”

About Med-Cannabis Pharma, Inc.

Med-Cannabis Pharma, Inc. (PINKSHEETS: MCPI) is a publicly-traded company focused on marijuana retail distribution, cultivation, and infused products in the emerging legal cannabis industry by investing in strategic asset growth through evaluating, financing, and purchasing.

With our core business of product development and market expansion in the growing cannabis and hemp industry, we invest in early-stage fully licensed marijuana companies and facilities that display solid growth potential, and are continuing to independently pursue licensing in states where marijuana is legal.

The Company recognizes that its product is believed to improve the quality of life of individuals suffering from certain medical conditions. Med-Cannabis Pharma, Inc. intends to best serve the community with the safest and highest quality products while maintaining a high degree of transparency, control, and compliance to preserve its assets, foster growth, and add long-term value to shareholders.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. The Company does not undertake any duty nor does it intend to update the results of these forward-looking statements.

For more information please visit us at www.med-cannabispharma.com

Contact Information

GRACIELA MORENO
President
Med-Cannabis Pharma, Inc.
+1 214 666 8364

SOURCE: Med-Cannabis Pharma, Inc.

ReleaseID: 432255